Flexion Therapeutics, Inc. | TalkMarkets

Latest Posts

Flexion Price Target Raised To $25 From $19 At Benchmark

Article By: The Fly

Friday, December 27, 2019 11:16 AM EDT

Benchmark analyst Bruce Jackson raised his price target for Flexion Therapeutics to $25 from $19 after the company received FDA approval to update the product label for Zilretta for the treatment of osteoarthritis knee pain.

In this article: FLXN

Read

Whither Flexion?

Article By: Ketan Desai

Sunday, November 24, 2019 1:13 PM EDT

A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.

In this article: FLXN

Read

3 Biotech And Pharma Stocks With Key FDA Catalysts This October

Article By: Arpita Dutt

Monday, October 2, 2017 10:16 AM EDT

The FDA, which approved 22 novel drugs last year, has given its approval to 34 drugs so far in 2017 including three in September.

In this article: FLXN, ALXN, PTCT Also: JNJ, TSRO, ACRX, AERI

Read

4 Sell-Ranked Drug Stocks To Avoid Ahead Of Q2 Earnings

Article By: Arpita Dutt

Monday, July 17, 2017 11:35 AM EDT

Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson & Johnson reporting second quarter results tomorrow before the market opens.

In this article: VRX, FLXN, RXDX, ANIK Also: JNJ, NVS

Read

Sanofi To Buy Flexion Therapeutics, Inc. For +$1 Billion In Cash

Article By: Lorimer Wilson

Thursday, March 23, 2017 6:04 PM EDT

Sanofi is in talks to buy Flexion Therapeutics, Inc. a Boston-area biotech with its lead product now awaiting FDA approval, for more than $1 billion in cash, according to a source close to the deal.

In this article: SNY, FLXN Also: JNJ, PFE

Read

All Posts